Crystal structure of the VRC01-class antibody 7A03 derived from GT1.1 vaccination

Precise targeting of HIV broadly neutralizing antibody precursors in humans.

QVQLVQSGAEVKKPGASVKVSCKASGYTFDDYYMHWVRQAPGQGLEWMGWMNPKTGGVNYAQRFQGRVTMTRDRSIDTAY
MELNSLRSDDTAMYYCARDYGGGYPLDFWGQGTLVTVFNQIKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC

QSALTQPASVSGSPGQSITISCIGTSSDNVSWYQHHPGKAPKLMIYEVDNRPSGVSARFSGSKSGNTASLTISGLQAEDE
ADYYCSSYEVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSK
QSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC

20% PEG-1000, 0.2 M Lithium sulfate, phosphate-citrate pH 4.2

National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)

HIV-1, Germline-targeting vaccination, CD4bs mAb, IMMUNE SYSTEM